Stoneridge Investment Partners LLC Makes New $55,000 Investment in Sight Sciences, Inc. (NASDAQ:SGHT)

Stoneridge Investment Partners LLC acquired a new position in shares of Sight Sciences, Inc. (NASDAQ:SGHT) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 15,235 shares of the company’s stock, valued at approximately $55,000.

Several other large investors also recently made changes to their positions in SGHT. KCK LTD. acquired a new position in shares of Sight Sciences during the 4th quarter worth about $15,925,000. Millrace Asset Group Inc. acquired a new position in Sight Sciences during the third quarter worth approximately $874,000. State Street Corp raised its stake in Sight Sciences by 17.4% in the third quarter. State Street Corp now owns 646,776 shares of the company’s stock valued at $4,075,000 after buying an additional 95,843 shares during the period. Jacobs Levy Equity Management Inc. lifted its position in shares of Sight Sciences by 46.3% in the third quarter. Jacobs Levy Equity Management Inc. now owns 207,893 shares of the company’s stock valued at $1,310,000 after buying an additional 65,767 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of Sight Sciences by 335.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 69,660 shares of the company’s stock worth $439,000 after acquiring an additional 53,658 shares during the period. Institutional investors and hedge funds own 55.51% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Lake Street Capital dropped their price target on Sight Sciences from $5.00 to $3.00 and set a “hold” rating on the stock in a research note on Wednesday, January 15th. UBS Group cut their target price on shares of Sight Sciences from $5.50 to $5.00 and set a “buy” rating for the company in a research note on Monday, January 27th. Needham & Company LLC reiterated a “hold” rating on shares of Sight Sciences in a research note on Tuesday, January 14th. Piper Sandler restated a “neutral” rating and set a $5.50 price objective (down from $6.00) on shares of Sight Sciences in a research report on Friday, November 8th. Finally, Stifel Nicolaus reduced their price objective on Sight Sciences from $6.00 to $5.00 and set a “buy” rating for the company in a report on Thursday. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $4.68.

Insider Transactions at Sight Sciences

In other news, CEO Paul Badawi sold 24,819 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $2.92, for a total transaction of $72,471.48. Following the completion of the sale, the chief executive officer now owns 5,676,331 shares of the company’s stock, valued at approximately $16,574,886.52. This represents a 0.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last three months, insiders have purchased 15,000 shares of company stock valued at $58,232 and have sold 63,014 shares valued at $197,295. 28.90% of the stock is currently owned by insiders.

Sight Sciences Trading Up 2.2 %

NASDAQ SGHT opened at $2.77 on Friday. The firm has a 50-day moving average price of $3.33 and a two-hundred day moving average price of $4.95. Sight Sciences, Inc. has a 12-month low of $2.67 and a 12-month high of $8.45. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.18 and a quick ratio of 9.74.

Sight Sciences (NASDAQ:SGHT) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. The business had revenue of $20.16 million for the quarter, compared to the consensus estimate of $20.41 million. On average, equities analysts predict that Sight Sciences, Inc. will post -1 earnings per share for the current year.

Sight Sciences Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.